Updated Aug. 9, 2022 3:59 pm ET / Original Aug. 10, 2022 3:00 am ET Order Reprints Print Article Dan Kitwood - WPA Pool/Getty Images Pfizer $5.4 billion deal to acquire the biotech Global Blood Therapeutics continued a year-long $26.4 billion buying spree, as the company puts its Covid-19 windfall to work shoring up its long-term revenue picture. The M&A campaign undertaken by Pfizer (ticker: PFE) stands in contrast to the strategy of its rival Moderna (MRNA), which has done no M&A so far, instead spending its Covid-19 cash on its own pipeline and stock buybacks.

https://www.barrons.com/articles/pfizer-moderna-stock-price-covid-deal-spending-spree-51660065154

#barrons